A Study of Ribavirin to Treat M4 and M5 Acute Myelocytic Leukemia (Borden-001)

This study has been completed.
Sponsor:
Collaborator:
The Leukemia and Lymphoma Society
Information provided by:
Jewish General Hospital
ClinicalTrials.gov Identifier:
NCT00559091
First received: November 15, 2007
Last updated: May 6, 2011
Last verified: September 2009
  Purpose

The purpose of this study is to determine if ribavirin (a drug commonly used to treat hepatitis C) also has activity in the treatment of patients with refractory or relapsed acute myeloid leukemia (AML) of the M4 and M5 subtype.


Condition Intervention Phase
Acute Myelocytic Leukemia
Drug: ribavirin
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Study of Ribavirin in Refractory of Relapsed Acute Myelocytic Leukemia M4 and M5 Subtypes

Resource links provided by NLM:


Further study details as provided by Jewish General Hospital:

Primary Outcome Measures:
  • Measure: Overall response rate [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Measure: Safety and tolerability, correlative studies [ Time Frame: 6 months ]

Estimated Enrollment: 25
Study Start Date: April 2007
Study Completion Date: February 2010
Primary Completion Date: February 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: I
Ribavirin
Drug: ribavirin
Ribavirin will be administered orally, twice daily, in the morning and evening with food. The dose selected is 400 mg AM and 600 mg PM. Intrapatient dose escalations can also be performed in defined circumstances. The maximal dose administered will be 1000 mg AM and 1000 mg PM.
Other Name: Ribasphere (Three Rivers Pharmaceuticals)

Detailed Description:

The eukaryotic translation initiation factor eIF4E is dysregulated in many human malignancies, including a subset of myeloid leukemia (M4/M5 AML and blast crisis CML). eIF4E overexpression leads to oncogenic transformation. Ribavirin impedes eIF4E mediated transformation in vitro, in primary human specimens and in animal models.

While ribavirin has been used extensively for the treatment of viral hepatitis C and its safety profile has been well defined, it has never been used in patients with AML. This study will establish the efficacy and safety of ribavirin in M4/M5 AML patients. In addition, this study will also include correlative studies to determine the effect of ribavirin on eIF4E activity and eIF4E related pathways in M4/M5 AML patients.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • A diagnosis of acute myeloid leukemia (AML), either M4 or M5 subtype de novo or resulting from a transformation from MDS or a myeloproliferative disorder.
  • Patients with AML who (a) have failed primary therapy -defined as failing two induction chemotherapies, (b) have relapsed or (c) are not suitable for intensive induction chemotherapy will be eligible. OR
  • Patients with AML blast crisis from CML if they are not suitable candidates for intensive induction chemotherapy or have failed imatinib mesylate OR
  • Patients with secondary AML after MDS if they are not suitable candidates for intensive induction chemotherapy.
  • ECOG 0,1,2, or 3
  • Life expectancy > 12 weeks.
  • Adequate renal and hepatic function

Exclusion Criteria:

  • Uncontrolled central nervous system involvement by AML
  • Active cardiovascular disease as defined by NYHA class III-IV categorization.
  • Intercurrent illness or medical condition precluding safe administration of ribavirin.
  • Received any previous therapy within 28 days prior to study entry.Hydrea is permitted but must be stopped 7 days prior to starting study drug.
  • Known infection with HIV.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00559091

Locations
Canada, Ontario
McMaster Hospital
Hamilton, Ontario, Canada, L8N 3Z5
Canada, Quebec
Jewish General Hospital
Montreal, Quebec, Canada, H4T 1E2
Maisonneuve-Rosemont Hospital
Montreal, Quebec, Canada, H1T 2M4
Sponsors and Collaborators
Jewish General Hospital
The Leukemia and Lymphoma Society
Investigators
Principal Investigator: Sarit Assouline, MD Jewish General Hospital
Study Director: Kathy Borden, PhD Université de Montréal
  More Information

Additional Information:
Publications:
Responsible Party: Dr. Sarit Assouline / Associate Director, Clinical Research Unit, Jewish General Hospital, McGill University
ClinicalTrials.gov Identifier: NCT00559091     History of Changes
Other Study ID Numbers: CR0620KB, REC:06-112
Study First Received: November 15, 2007
Last Updated: May 6, 2011
Health Authority: Canada: Health Canada

Keywords provided by Jewish General Hospital:
AML
Acute myelocytic leukemia
leukemia
relapsed
refractory
M4
M5

Additional relevant MeSH terms:
Leukemia
Leukemia, Myeloid, Acute
Leukemia, Myeloid
Neoplasms by Histologic Type
Neoplasms
Ribavirin
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Antiviral Agents
Anti-Infective Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on August 20, 2014